Clinical trials: Nutrition Disorder
Obesity
A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED)
This study will test the hypotheses that a single dose of oxyntomodulin (OXM) will be neutral or better than placebo in lowering ambient glucose levels during a graded glucose infusion (GGI) and that a single dose of OXM will…
- Trial name
- NCT01055340
- Testing
- Oxyntomodulin (OXM), Comparator: Oxyntomodulin (OXM)
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, Overweight
A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight
The purpose of the study is to determine the effect of semaglutide on gastric emptying in people with obesity. Participants will receive either semaglutide or placebo, and the treatment assigned will be decided by chance.
- Trial name
- NCT07845578
- Testing
- Semaglutide, Paracetamol
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Comparative Study of KES524 in Patients With Obesity Disease
To investigate the efficacy and safety of KES524 in patients with obesity (visceral fat obesity with type 2 diabetes and dyslipidemia), a 52-week, double-blind, placebo-controlled comparative study is conducted.
- Trial name
- NCT00165685
- Testing
- Sibutramine Hydrochloride Monohydrate
- Where
- 20 sites in Japan
- Sponsor
- Eisai Limited
Metabolism and Nutrition Disorder, Obesity
Awareness, Care & Treatment in Obesity Management (ACTION) Study
The ACTION (Awareness, Care, and Treatment In Obesity management) study aims to identify perceptions, attitudes, behaviours, and potential barriers to effective obesity care across three respondent types: 1) People with Obesity…
- Trial name
- ACTION (NCT03223493)
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 3,767 people
- Sponsor
- Novo Nordisk A/S
Dysphagia, Malnutrition
IDDSI Nutritional Drink for Dysphagia Study
This study will evaluate the gastrointestinal (GI) tolerance, compliance , acceptability and safety of a ready-to-use oral nutritional supplement drink for patients with dysphagia.
- Trial name
- NCT03679078
- Testing
- IDDSI nutritional supplement drink
- Where
- 8 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Nutricia UK Ltd
Overweight and Obesity
Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus
The study is designed to evaluate the preliminary efficacy, safety, population PK profile, and immunogenicity of CPX101 in subjects with obesity or overweight with weight related comorbidities but without diabetes mellitus.
- Trial name
- NCT06532578
- Where
- Australia
- Volunteers
- 240 people
- Sponsor
- Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
Cachexia
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
- Trial name
- NCT01433263
- Testing
- BYM338 active drug
- Where
- 10 sites in United States, Lithuania and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Obesity
Effects of PrimaVie and Exercise Training on Human Skeletal Muscle (PrimaVie)
PrimaVie (Natreon Inc), is a a purified and standardized shilajit extract for nutraceutical use. Research indicates that PrimaVie® has targeted action for increasing energy, revitalization and anti-aging.
- Trial name
- NCT02026414
- Testing
- PrimaVie, Exercise
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Sanni Raju
Hypophosphatasia (HPP)
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
This study aims to characterize the natural history of patients with severe perinatal or infantile onset HPP.
- Trial name
- NCT01419028
- Where
- 12 sites in United States, Australia and 5 more
- Volunteers
- 48 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Overweight/Obesity
A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b clinical study. All trial participants are required to use TQF3250 capsules or placebo.
- Trial name
- NCT07798284
- Testing
- TQF3250 capsules
- Where
- 10 sites in China
- Volunteers
- 80 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Obesity
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
This study is open to adults between 18 and 65 years of age who have obesity. People can join the study if they have a body mass index (BMI) between 30 and 45 km/m².
- Trial name
- NCT06745284
- Testing
- Survodutide, Semaglutide
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.
A study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD9567.
- Trial name
- NCT02760316
- Testing
- AZD9567 10 mg, AZD9567 20 mg, AZD9567 40 mg
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Prader-Willi Syndrome
Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome
The primary objective of this study is to assess the efficacy of cannabidiol oral solution on hyperphagia-related behavior in patients with Prader-Willi Syndrome (PWS).
- Trial name
- NCT02844933
- Testing
- Cannabidiol
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Mild Cognitive Impairment, Dementia
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
This retrospective study is a more extensive, confirmatory analysis of the cognitive and functional outcomes initially seen in 2 groups of MCI/dementia patients in Springfield, MA and compares specialized dementia care and a…
- Conditions
- Mild Cognitive Impairment, Dementia, Hypoxia, Hyperhomocysteinemia
- Trial name
- NCT02860338
- Volunteers
- 900 people
- Sponsor
- Clionsky Neuro Systems Inc.
Cardiovascular Risk Factors, Hyperlipidemia
European Study of Cardiovascular Risk
The main objective of this study is to describe the management of patients with cardiovascular risk factors in primary prevention among different European countries.
- Conditions
- Cardiovascular Risk Factors, Hyperlipidemia, Hypertension, Diabetes
- Trial name
- EURIKA (NCT00882336)
- Where
- 775 sites in Austria, Belgium and 10 more
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca
Obesity, Overweight
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.
- Conditions
- Obesity, Overweight, Weight Maintenance
- Trial name
- NCT07553299
- Testing
- VRB-101
- Where
- 20 sites in United States
- Volunteers
- 8 people
- Sponsor
- Verdiva Bio Dev Limited
Overweight or Obesity and Elevated Liver Fat
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver…
- Trial name
- NCT07441252
- Testing
- Maridebart cafraglutide
- Where
- 23 sites in United States
- Volunteers
- 180 people
- Sponsor
- Amgen
Obesity, Weight Loss
Attitudes Toward Food During a Weight Loss Intervention
The purpose of this study is to evaluate whether the Noom Healthy Weight Program, a digital behavior change weight loss intervention, creates a positive relationship with food, compared to a waitlist control group.
- Conditions
- Obesity, Weight Loss, Overweight and Obesity, Overweight or Obesity
- Trial name
- NCT04586647
- Testing
- Noom Healthy Weight; mobile behavior change program for weight loss.
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Diabetes Mellitus, Type 1, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity.
- Conditions
- Diabetes Mellitus, Type 1, Overweight, Obesity
- Trial name
- NCT07803744
- Testing
- Tirzepatide, Acetaminophen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
Nonalcoholic Steatohepatitis (NASH)
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
An Open-Label Part was added: This part will enroll in selected sites which are less affected by the COVID-19 pandemic. 150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized into 3 groups…
- Trial name
- ARMOR (NCT04104321)
- Testing
- Aramchol free acid
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- Galmed Research and Development, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.